Description
Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The antitumor efficacy of bispecific T cell engager-secreting STAb-T cells has been demonstrated in several mouse models.
Creative Biolabs provides a complete list of ready-to-use CD3-X BsAb Secreting T Cell Redirecting Vector, which are artificial vectors designed to engineer T lymphocytes, resulting in T cell cytokine secretion and cytotoxic effector function. The T cell-redirecting CD3-X vectors can be used to develop STAb-based immunotherapies